Lyra Therapeutics (LYRA) Total Non-Current Liabilities (2019 - 2025)

Lyra Therapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $48.0 million in Q3 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 17.37% year-over-year to $48.0 million in Q3 2025; TTM through Sep 2025 was $48.0 million, a 17.37% decrease from a year earlier, with the FY2024 full-year figure at $54.8 million, up 2.96% from the prior year.
• Total Non-Current Liabilities was $48.0 million for Q3 2025 at Lyra Therapeutics, down from $51.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $64.0 million in Q1 2024, with the low at $5.4 million in Q1 2021.
• Average Total Non-Current Liabilities over 5 years is $38.3 million, with a median of $36.3 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities decreased 26.99% in 2021, then surged 348.9% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $20.6 million in 2021, then surged by 42.15% to $29.2 million in 2022, then jumped by 82.04% to $53.2 million in 2023, then rose by 2.96% to $54.8 million in 2024, then dropped by 12.26% to $48.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $48.0 million (Q3 2025), $51.0 million (Q2 2025), and $52.4 million (Q1 2025), per Business Quant data.